Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | 7 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 280 Parkinson's papers of 6,387 | 0.26 |
| pathways Reactome | 4 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 5463
Sealed predictions
- FUS in dopamine neurons, braak+0.25 (p 0.520) → -0.01 (p 0.982)receipt 5471
Swarm cases
receipt 5471: FUS in dopamine neurons, braak
- power
- full sample +0.20 (p 0.418, n 18), 95% CI -0.29 to +0.61. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.16 (p 0.526, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.24 (p 0.346, n 18). could be the mix.
- skeptic
- leave-one-out range +0.10 to +0.31, sign flips 0; without severely affected donors +0.20 (p 0.418, n 18). fragile.
- cell type
- strongest in astrocytes: +0.66 (p 0.0028, n 18) vs +0.20 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FUS in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up FUS · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.78 p 0.0059 (needs p < 3.6e-4)
Receipts
loading the receipts